Arctic Bioscience AS(DE:9TD)
€0.18+0.02 (+16.67%)
DE:9TD
Arctic Bioscience AS financials statements
€0.18
At close:+0.02 (+16.67%)
Arctic Bioscience AS (9TD) Ratios
1 Followers
Arctic Bioscience AS Ratios
DE:9TD's free cash flow for Q2 2026 was kr-18.63M. For the 2026 fiscal year, DE:9TD's free cash flow was decreased by kr-1.29M and operating cash flow was kr-17.34M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.59 | 0.86 | 3.36 | 4.91 | 12.76 |
| Quick Ratio | 0.24 | 0.43 | 2.53 | 4.03 | 11.40 |
| Cash Ratio | 0.02 | 0.03 | 2.01 | 3.57 | 10.87 |
| Solvency Ratio | -0.32 | -0.62 | -0.96 | -0.75 | -1.91 |
| Operating Cash Flow Ratio | -0.27 | -0.67 | -1.02 | -0.63 | -1.89 |
| Short-Term Operating Cash Flow Coverage | -0.66 | -1.45 | -11.41 | -23.16 | -9436.79 |
| Net Current Asset Value | kr -61.85M | kr -11.12M | kr 91.46M | kr 157.90M | kr 246.01M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.22 | 0.12 | 0.01 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.36 | 0.16 | 0.01 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.26 | 0.13 | 0.01 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.14 | 0.00 | 0.01 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.64 | 1.33 | 1.16 | 1.14 | 1.07 |
| Debt Service Coverage Ratio | -0.69 | -1.15 | -12.24 | -27.52 | -17.85 |
| Interest Coverage Ratio | -3.47 | -15.18 | 0.00 | -8868.39 | 19.13 |
| Debt to Market Cap | 0.70 | 0.67 | 0.02 | 0.00 | 0.00 |
| Interest Debt Per Share | 2.70 | 1.42 | 0.08 | 0.05 | 0.09 |
| Net Debt to EBITDA | -1.98 | -0.77 | 1.80 | 4.72 | 5.99 |
| Profitability Margins | |||||
| Gross Profit Margin | -84.07% | 27.34% | 28.97% | 33.98% | 23.98% |
| EBIT Margin | -89.71% | -102.99% | -143.93% | -99.27% | -188.05% |
| EBITDA Margin | -76.95% | -91.15% | -127.99% | -88.38% | -176.35% |
| Operating Profit Margin | -89.71% | -109.90% | -143.93% | -109.10% | 188.60% |
| Pretax Profit Margin | -102.32% | -110.23% | -134.84% | -99.28% | -197.91% |
| Net Profit Margin | -102.32% | -110.23% | -134.84% | -99.28% | -197.91% |
| Continuous Operations Profit Margin | -102.32% | -110.23% | -134.84% | -99.28% | -197.91% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 114.05% | 100.30% | 93.68% | 91.00% | -104.93% |
| Return on Assets (ROA) | -14.41% | -17.13% | -15.16% | -10.38% | -12.47% |
| Return on Equity (ROE) | -23.65% | -22.75% | -17.60% | -11.84% | -13.28% |
| Return on Capital Employed (ROCE) | -17.84% | -22.52% | -18.64% | -13.01% | 12.66% |
| Return on Invested Capital (ROIC) | -15.25% | -19.62% | -18.39% | -12.97% | 12.66% |
| Return on Tangible Assets | -56.88% | -58.21% | -28.52% | -15.42% | -15.05% |
| Earnings Yield | -46.40% | -102.97% | -17.05% | -11.83% | -9.84% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.18 | 1.70 | 1.63 | 1.83 | 1.95 |
| Payables Turnover | 2.84 | 1.67 | 1.30 | 1.24 | 1.96 |
| Inventory Turnover | 2.49 | 1.09 | 0.73 | 0.64 | 0.57 |
| Fixed Asset Turnover | 1.76 | 1.78 | 1.28 | 1.53 | 1.35 |
| Asset Turnover | 0.14 | 0.16 | 0.11 | 0.10 | 0.06 |
| Working Capital Turnover Ratio | -1.85 | 1.04 | 0.27 | 0.17 | 0.16 |
| Cash Conversion Cycle | 185.31 | 330.73 | 443.95 | 476.91 | 637.41 |
| Days of Sales Outstanding | 167.53 | 215.07 | 224.47 | 199.29 | 187.39 |
| Days of Inventory Outstanding | 146.50 | 334.86 | 499.23 | 572.08 | 636.58 |
| Days of Payables Outstanding | 128.72 | 219.20 | 279.74 | 294.47 | 186.55 |
| Operating Cycle | 314.03 | 549.93 | 723.70 | 771.38 | 823.96 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.84 | -1.78 | -1.58 | -1.04 | -1.63 |
| Free Cash Flow Per Share | -1.68 | -3.78 | -3.37 | -3.44 | -3.13 |
| Dividend Paid and CapEx Coverage Ratio | -1.00 | -0.89 | -0.89 | -0.43 | -1.08 |
| Capital Expenditure Coverage Ratio | -1.00 | -0.89 | -0.89 | -0.43 | -1.08 |
| Operating Cash Flow Coverage Ratio | -0.36 | -1.38 | -19.66 | -23.16 | -9436.79 |
| Operating Cash Flow to Sales Ratio | -0.56 | -1.04 | -1.19 | -0.74 | -1.84 |
| Free Cash Flow Yield | -51.35% | -206.60% | -32.07% | -29.19% | -17.57% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -2.16 | -0.97 | -5.87 | -8.45 | -10.16 |
| Price-to-Sales (P/S) Ratio | 2.21 | 1.07 | 7.91 | 8.39 | 20.10 |
| Price-to-Book (P/B) Ratio | 0.51 | 0.22 | 1.03 | 1.00 | 1.35 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.95 | -0.48 | -3.12 | -3.43 | -5.69 |
| Price-to-Operating Cash Flow Ratio | -3.90 | -1.03 | -6.63 | -11.33 | -10.95 |
| Price-to-Earnings Growth (PEG) Ratio | 0.11 | -0.19 | -0.21 | 0.42 | -0.12 |
| Enterprise Value Multiple | -4.84 | -1.95 | -4.38 | -4.77 | -5.41 |
| Enterprise Value | 149.45M | 77.25M | 189.43M | 144.58M | 205.17M |
| EV to EBITDA | -4.84 | -1.95 | -4.38 | -4.77 | -5.41 |
| EV to Sales | 3.73 | 1.78 | 5.61 | 4.22 | 9.54 |
| EV to Free Cash Flow | -3.29 | -0.80 | -2.21 | -1.72 | -2.70 |
| EV to Operating Cash Flow | -6.60 | -1.70 | -4.70 | -5.69 | -5.20 |
| Tangible Book Value Per Share | -1.45 | 0.52 | 4.64 | 7.39 | 10.78 |
| Shareholders’ Equity Per Share | 6.44 | 8.28 | 10.17 | 11.79 | 13.19 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 1.49 | 1.71 | 1.33 | 1.41 | 0.89 |
| Net Income Per Share | -1.52 | -1.88 | -1.79 | -1.40 | -1.75 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.14 | 1.07 | 0.94 | 1.00 | 1.05 |
| Research & Development to Revenue | 0.00 | 0.05 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.60 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.55 | 0.95 | 0.89 | 0.75 | 0.93 |
Currency in NOK
